gsk356278
Small moleculeexperimental
Clinical trial activity
3 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Nov 1, 2009 (NCT01031186)
Timeline
2000s
- Jan 1, 2009
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Phosphodiesterase 4BINHIBITOR
PDE4B inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- 5-(5-((2,4-dimethylthiazol-5-yl)methyl)-1,3,4-oxadiazol-2-yl)-1-ethyl-n-(tetrahydro-2h-pyran-4-yl)-1h-pyrazolo(3,4-b)pyridin-4-amine
- gsk356278
- gsk356278
- gsk356278
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01573819 | Phase 1 | Nov 24, 2011 | GlaxoSmithKline |
| NCT01602900 | Phase 1 | Nov 22, 2011 | GlaxoSmithKline |
| NCT01031186 | Phase 1 | Nov 1, 2009 | GlaxoSmithKline |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| GlaxoSmithKline | For profit | 3 | 3 | 1 | 2009 |
1 organizations
Page 1 / 1